Home > Members > Board Resources > Electronic Mailbag > April 2026 Electronic Mailbags

---

Deadline Approaching – Submissions for 2026-2027 Committees and Task Forces

The National Association of Boards of Pharmacy (NABP) is seeking volunteers from its active member boards of pharmacy to serve on the 2026-2027 committees and task forces. Executive officers and board members, including public members, interested in serving on a committee or task force are encouraged to submit a letter of interest and a current resume or curriculum vitae. In addition, NABP encourages affiliated members from associate member boards and interested board of pharmacy staff to volunteer for NABP task forces. Submissions should outline volunteers’ applicable experiences and accomplishments, along with the reasons they wish to be considered for appointment to a committee or task force.

Task Force or Standing Committee	Eligible to Serve
Single-Issue Task Force or Work Group	Current or past board members and staff from active and associate member boards
Committee on Law Enforcement/Legislation	Current board members and executive officers of active member boards
Committee on Constitution and Bylaws	Current board members and executive officers of active member boards
Advisory Committee on Examinations (ACE)1	Current board members and executive officers of active member boards or those who have served within the last five years as a board member or executive officer of an active member board

All submissions must be sent to NABP Executive Director/Secretary Lemrey “Al” Carter, PharmD, MS, RPh, at ExecOffice@nabp.pharmacy or via the NABP website, by Friday, May 15, 2026. All materials will be forwarded to NABP President-elect Nicole L. Chopski, PharmD, ANP, who will make the appointments when she becomes NABP President following the Association’s 122^nd Annual Meeting, May 12-15, 2026.

¹ACE submissions are due by December 31, 2026, and will be considered for appointment in 2027.

back to top

FDA Reminder: Certain Conditions Must be Met for Compounded Drugs to Qualify for Exemptions under Section 503A and 503B of the FD&C Act

On April 1, 2026, the FDA issued an updated Drug Alert and Statement reminding compounders that certain conditions must be met for compounded drugs to qualify for the exemptions under sections 503A and 503B of the FD&C Act.

503A Pharmacy and Prescriber Compounding

For pharmacies and prescribers to qualify for the exemptions under 503A, the drug product must be compounded for an individual patient based on receipt of a prescription, and the compounder does not compound, regularly or in inordinate amounts, any products that are essentially copies of commercially available drugs.

Pharmacies and prescribers may not regularly compound drug products that are essentially copies of commercially available drugs. In guidance, the FDA intends to consider a compounded drug product to be essentially a copy of a commercially available drug product if the compounded drug has:

• The same Active Pharmaceutical Ingredient (API)
• The same, similar, or easily substitutable strength
• The same route of administration.

This is unless a prescriber determines and documents that the compounded drug product contains a change that produces a significant difference from the commercially available drug product for a specific patient.

The FDA also intends to consider a compounded drug product to be essentially a copy of a commercially available drug if:

• The compounded drug product contains the same APIs as 2 or more commercially available drug products in the same, similar, or easily substitutable strength and
• The commercially available drug product can be used (regardless of how it is labeled) by the same route of administration prescribed for the compounded drug product, unless there is documentation of a prescriber determination of a significant difference.

The FDA does not intend to take enforcement action against a pharmacy or prescriber who fills 4 or fewer prescriptions for an “essentially a copy” product per calendar month.

503B Outsourcing Facility Compounding

Outsourcing facilities are restricted from compounding drugs using bulk drug substances (or API) unless:

• The bulk drug substance appears on a list identifying bulk drug substances for which there is a clinical need, which is referred to as the 503B bulks list or
• The drug compounded from the bulk drug substance is on the FDA’s drug shortage list at the time of compounding, distribution, and dispensing.

Tirzepatide and semaglutide do not currently appear on the 503B bulks list or on the FDA’s drug shortage list.

back to top

Proposed Amendments to the NABP Constitution and Bylaws 122^nd NABP Annual Meeting, May 12-15, 2026

The NABP Constitution and Bylaws is a carefully constructed document that has guided the Association well for its 122 years of existence. Over the course of that time, the Constitution and Bylaws have been amended by the membership when warranted.

In May of this year at the 122^nd NABP Annual Meeting, the NABP membership will hear and vote on 2 proposed amendments to the NABP Constitution that were first presented at last year’s Annual Meeting. Additionally, the membership will hear 5 newly proposed amendments to the NABP Constitution. In accordance with Article VI, Section 3(b) of the NABP Constitution, the newly proposed amendments will be discussed and voted on at the 123^rd NABP Annual Meeting to be held May 11-14, 2027, in New Orleans, LA.

Attached are the submitted amendments and summaries for your reference. The proposed amendments are being forwarded to you in accordance with the requirement of the Constitution and Bylaws to provide proposed amendments to the member jurisdictions at least 30 days prior to the Annual Meeting.

Contact Lemrey “Al” Carter, Executive Director/Secretary at ExecOffice@nabp.pharmacy if you have any questions.

Attachment

back to top